Qualigen Therapeutics President, COO and Director Amy Broidrick to resign effective June 16, 2023

AIxCrypto Holdings, Inc.

Amy Broidrick, President, Chief Strategy and Operating Officer, and director, submitted resignation effective June 16, 2023.
Her departure is not related to any disagreement with the company on operations, policies, or practices.
She will resign from all officer and director positions with the company and its subsidiaries.
Company intends to enter into a separation agreement and general release with Ms. Broidrick.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Amy Broidrick

President, Chief Strategy and Operating Officer and Director

AIXC · AIxCrypto Holdings, Inc.

Effective: 2023-06-16
Filed: May 19, 2023, 7:59 PM ET

On May 16, 2023, Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which will become effective June 16, 2023 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Broidrick resigned as President, Chief Strategy and Operating Officer and Director at AIxCrypto Holdings, Inc..

Action: resigned
Role: President, Chief Strategy and Operating Officer and Director

Exact text from the filing

On May 16, 2023, Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which will become effective June 16, 2023 (the “Effective Date”).

View on SEC.gov

AIxCrypto Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-018231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.